Prognostic value of cystatin C in acute coronary syndrome

Mohammed Abdulwahid Shuaila, Hassanain M Saeed Abdulamir, Monem Makki Alshok

Objective  Coronary artery disease associated with an increment with a variety of markers, one of them Cystatin C, in this study we evaluate its role in a prospective study as prognostic marker, and evaluate the correlation between Cystatin C plasma level and variety of acute coronary syndrome (ACS) complications.

Methods  A total 51 patients who admitted for Merjan Teaching Hospital coronary care unit whom ACS was diagnosis was made depend on history, clinical examination and investigation, and then blood sample was taken to measure plasma level and follow up for 6 months of any new events including new ischemia, rehospitalization, electrical and mechanical complication.

Results  Patient who admitted with ACS with high level of cystatin C associated with more mortality (P value: 0.09) and more electrical complication (P value: 0.035) and more rehospitalization (P value: 0.01), but failed to show a correlation with mechanical complication.

Conclusion  Elevated level of Cystatin C in patient admitted to hospital with ACS associated with an increase in hospital mortality, electrical complication, and rehospitalization and lower ejection fraction than a patient with a normal Cystatin C level.

Keywords  cystatin C, prognostic value, acute coronary syndrome

Introduction

Cystatin C (cyt-C) is a small protein molecule (120 amino acid peptide chain, approximately 13kDa) produced by virtually all nucleated cells in the human body. It belongs to the family of papain-like cysteine proteases and its main biological role is the extracellular inhibition of cathepsins. It’s near constant production rate, the fact that it is freely filtered from the glomerular membrane and then completely reabsorbed without being secreted from the proximal tubular cells, made it an almost perfect candidate for estimating renal function. The strong correlation between chronic kidney disease (CKD) and cardiovascular disease (CVD) along with the growing understanding of the role of cysteinyl cathepsins in the pathophysiology of CVD inspired researchers to explore the potential association of cyt-C with CVD. A high level of cystatin C in the blood corresponds to a decreased glomerular filtration rate (GFR) and hence to kidney dysfunction. Recent studies suggest that increased levels of cyt-C may also indicate an increased risk of heart disease, heart failure, stroke, and mortality.1-3,6-8 There is a close relationship between cystatin C and acute ischemic stroke, independently of conventional risk factors.3 Several studies mentioned that increased levels of cyt-C are found in patients with coronary artery disease.6,17 Cystatin C recently, it has been studied for its role in predicting new-onset or deteriorating cardiovascular disease. Also cyt-C may be an indicator of acute PTE (pulmonary thromboembolism) in patients with normal renal function. Also elevated serum Cystatin C levels may predict venous thrombosis beyond reflecting impaired kidney function. Cystatin C is known to modulate the neutrophil chemotactic activity and may inhibit prothrombotic activity of proteolytic substances secreted by activated neutrophils. Thus, it may be hypothesized that increased serum levels of cyt-C represent an inadequate counterbalancing mechanism to avoid thrombosis formation.8,13-17 A recent study conducted by Urbanovici et al. demonstrated that higher serum cyt-C levels independently predicted 3-year all-cause and CVS mortality in symptomatic peripheral arterial disease patients with normal renal function. In accordance with Urbanovici et al.14 Loew

and colleagues15 have reported that only high plasma cyt-C levels (> 1.24 mg/l) were associated with risk of fatal and nonfatal cardiovascular events during the follow-up. Furthermore, in a recent meta-analysis, higher cyt-C levels were strongly and independently associated with specific endpoints like stroke, myocardial infarction and heart failure.20,21

The aim of the present study was to evaluate whether the concentration of Cyt C could predict the severity of coronary artery disease after myocardial infarction in patients with normal renal function estimated from the concentration of serum creatinine, and to determine the prognostic value of Cyt C in predicting cardiovascular mortality during the follow up of patients with acute coronary syndrome (ACS).

Methods

A short-term prospective study was conducted on 51 patients with ACS admitted to Merjan teaching hospital from the first of March 2015 to first of July 2015. Patients were excluded from the study if there is any neoplasia in any organ, pregnancy, thyroid dysfunction, altered mental state, renal impairment on admission, suspected dissected aortic aneurysm, recent MI (6 month ago), patients with eGFR less than 60 ml/kg/min, patient received steroid and any patient refuse participation. The diagnosis of ACS was established by symptoms, electrocardiography and cardiac biomarkers. Detailed history was taken from the patients, and physical examination was performed on admission. Echocardiography was done usually in the next day of admission, but bed-side echocardiography was done if there is a strong indication to assess hemodynamically unstable patients and to rule out mechanical complication in STEMI patients. Potential risk factors for ACS including hypertension (HPT), diabetes (DM), smoking, as well as age of patients, and other information were reviewed by direct questionnaire to the patients or their relatives. Risk factors were defined according to the protocol. The patients with a history of HPT or without history but compatible with JNC9 definition of hypertension mm Hg were defined hypertensive.
The patients who have the history of DM, being on glucose-lowering medication prior to ACS onset or without a history but who had fasting blood sugar more than 126 mg/dl or random blood sugar > 200 mg/dl on two occasions were defined diabetics. The patients were regarded as current smokers if they smoked until admission or stopped smoking within the last 3 months. GFR measured using MDRD equation (modification of diet in renal disease) as follows:

\[
eGFR \text{ ml/min. } 73m^2 = 175 \times S\. (S\. Cr) - 1.154 \times (\text{Age})^{-0.203} \times (0.742 \text{ if female}) \times (1.212 \text{ if black})
\]

We followed the patients daily during the period of hospitalization. Clinical assessment and echocardiography was done to the patients who discharged from hospital, on average of 6 to 8 weeks after discharge. The patients were followed up by telephone or outpatient clinic visits for up to 3 months.

**Blood sampling and laboratory methods**

Blood was drawn on admission at the time of inserting an intravenous line. The sample was collected into a plain tube, allowed to clot and then separate the serum by centrifuge using [Hettich Rotofix24] (A German 2005), centrifuge at a rate of 3000 rpm for 5 minutes. 0.5–1.0 ml of serum is stored at 2–8 Celsius for a few days for the measurement of Cystatin C level. Serum Cystatin C is measured by using (Nephelometric-immunoterbidimetric method). The other laboratory investigation included a complete blood count, and random blood glucose, urea and creatinine. Cardiac enzymes, including troponin, if indicated we perform a thyroid function test.

**Statistical Analysis**

Statistical analysis was performed using statistical package for social science version 20 “SPSS 20”. Categorical variable such as sex, diabetes, hypertension, smoking, occurrence of death was expressed as a percentage. The correlations between categorical variables were assessed using Chi square or Fisher exact test as appropriate. Continuous variables that were normally distributed such as the age of the patient, serum Cystatin C, duration of hospitalization were expressed as mean ± Standard deviation. The correlation between continuous variables were assessed using annova test. P value of 0.05 or less considered to be significant.

**Results**

In this study, 51 patients were enrolled. The age ranged from 45 to 65 (mean ± SD 52.12 ± 8.93), 32 of them were male, 19 were female, 12 patients (23.5%) were diabetes, 15 patients (29.4%) were hypertensive, 13 patients (25.4%) were current smokers. Of those patients, 36 patients (71%) were admitted with the diagnosis of STEMI, 15 patients (29%) admitted with the diagnosis of non-STEMI/UA, among patients with STEMI 20(28%) had anterior STEMI, 16(22%) had Inferior STEMI. In the UA/NSTEMI group 13(86%) of them have ST depression/T inversion, and 2(14%) have normal ECG findings. 33 patients (91%) had successful reperfusion therapy, 25 patients (69%) had PCI primary or rescue, and 8(22%) patients had thrombolysis as a sole reperfusion therapy. One patient developed acute ischemic stroke with slurred speech and dysphagia on the second day of hospitalization after primary PCI (with normal brain CT scan done immediately after the event) with the resolution of the neurological deficit during the follow up. The duration of hospitalization was 4 ± 1.82 days and mortality was 4 patients (7.5%). Table 2 shows the correlation between mortality and the patients’ clinical characteristics. The mean age of patients who died (55 ± 6.272), 3(75%) of them where males and 1(25%) where females, 2 (50%) were hypertensive with (0.22 P value), and 3(75%) were diabetics (0.036 P value), 3 (75%) were smokers (0.046 P value). Table 3 shows the correlation between cystatin...
level and mortality, rehospitalization, electrical and mechanical complications. In patients who died during the hospital course were 1.5250 ± 0.30838, while the mean cystatin C level in patients who were discharged alive from the hospital were between 0.8538 and 0.8531. The correlation was statistically significant (P value 0.009). 4 patients (19%) developed electrical complications in hospital. Two patients developed primary ventricular fibrillation (VF) were successfully resuscitated, one patient developed atrial fibrillation which rate controls done with intravenous amiodarone infusion, and one patient developed sustained ventricular tachycardia (VT) was successfully resuscitated with mean cystatin C (1.4150 ± 61016) SD developed electrical (P value 0.035 significant). Also our results showed correlation between Cystatin C level and ejection fraction (EF) using Spearman's correlation coefficient, which showed a negative correlation coefficient (−154). Nine patients (17.6%) readmitted to hospital, of those patient 4 patients admitted with decompensated heart failure, 2 patients admitted due to post MI angina, 2 patients due to acute pulmonary edema, and 1 patient due to VSR. With mean 1.3833 and std. deviation 0.40159. VSR in which 1 patient (1.9%) developed VSR. This patient developed clinical deterioration with hemodynamic instability and developed a new murmur with auscultation, ECHO approves the presence of acquired VSD and the patient referred for urgent surgical intervention (P value 0.1 non-significant).

**Discussion**

In this study, we have found that an increase in Cystatin-C level is associated with an increase in hospital mortality. This result has agreed with Osama Tayeh et al. Their study was a non-randomised controlled trial took place in Egypt, prospectively has conducted on 75 patients with (ACS) and also an equal number of controls. Patients who have included in this study are presented with ACS and evaluated the prognostic value of it as a predictor for the major acute coronary event. Our concern study has shown that group with high Cystatin C level is associated with significant in hospital mortality (P value 0.025), and also it is going with Leila Abid et al. Which showed (P value 0.01 clinically significant). And another study where Cystatin C was used as a prognostic biomarker in STEMI and Shlipak et al. Eriksson et al. have asserted that an increase in cholesterol or LDL-cholesterol levels are considered as risk factors of IHD, but CYS-C may reflect precisely the presence or absence of CAD. We found in this study that diabetes and smoking are associated with increasing mortality that agrees with Osama Tayehetal. and presenting significant correlation with smoking and disagree with Leila Abidetal. (non-significant). While in a multivariate regression analysis between the prevalence of high CYS-C and other common traditional risk factors, including: hypertension, diabetes, and smoking if all risk factors are present, the patient had a high CYS-C level. Meanwhile hypertensive was clinical regarded as nonsignificant (P value 0.22). The reasonable explanation for our results is that serum cystatin C has regarded as the most sensitive marker of early renal dysfunction, due to that it may be involved in the process of coronary heart disease. Despite the uncertainty of the exact mechanisms underlying the predictive role of cystatin C in CHD, evidence suggests that elevated serum cystatin C is associated with worse prognosis in patients with CHD. A study by Zethelius et al. have declared whether a combination of biomarkers, including N-terminal pro-brain natriuretic peptide, cystatin C, troponin, and hs-CRP, have improved patient stratification of risk compared with established cardiovascular risk factors. Those researchers have discovered that adding cystatin C to the system significantly will improve predictive efficacy. Also, we found that higher patient with higher level of Cystatin C levels have associated with increased incidence in hospital electrical complications (P value 0.035), and this agrees with Ahmed Abid et al. who have confirmed that higher level of Cystatin C is associated with a higher chance of electrical complications (P value 0.029). And we also found that high level of Cystatin C associated with higher rehospitalization due to various causes (decompensated heart failure, post MI angina, pulmonary edema, etc.) that agreed with Ichimoto et al., whom investigated the Cystatin C level of 71 patients with STEMI, had also suggested the prognostic value of Cys C, high concentrations of this marker were associated with greater frequency of rehospitalization and acute heart failure episodes. Association of Cystatin C with greater mortality rate during follow-up. Kilic et al. have investigated 160 patients hospitalized with ACS and demonstrated that the admission of the serum CYS-C level was significantly associated with future cardiovascular complications and rehospitalization and mortality during 12 months of follow-up. It also agrees with Osman Tayeh and Axel Akerblom et al. Higher level of Cystatin C is associated with lower ejection fraction (Spearman’s correlation coefficient which showed a negative correlation coefficient (−0.154). This also has agreed with Moran et al. who have concluded that CYS-C can be a marker of heart failure, and its combination with N-terminal pro-B-type natriuretic peptide (NT-Pro-BNP) considered to be as good marker than CYS-C alone for predicting cardiovascular mortality, especially in elderly patients with heart failure. Our study agrees with Garcia Acuna et al. who indicated that an elevated serum CYS-C level will predict the development of myocardial infarction, heart failure and cardiovascular death in 203 patients hospitalized with high-risk ACS, independent of other classical risk factors either in-hospital or during a 6-month follow-up period. The results of our study also have agreed with Silva et al. who have suggested that patients admitted for ST elevation myocardial infarction and who presented elevated Cys C levels (P 0.84 mg/L) on admission, had greater risk of progression to cardiogenic shock or death during hospitalization. In this same study, only Cys C levels P 0.84 mg/L and impaired LVEF < 40% were the predictors of the risk of death during the follow-up. And also agreed with Ichimoto et al. and Osman et al. Mechanical complications have shown non-significant results (P value 0.1), which had disagreed with Osman Tayeh et al. (P value 0.002), and this might be due to small a number of data that we have used in our study.

**Conclusion**

Elevated level of Cystatin C in patients admitted to the hospital with ACS associated with an increase in hospital mortality, electrical complication, and rehospitalization and lower ejection fraction than a patient with a normal Cystatin C level. We recommend measuring the Cystatin C level with early hours of admission for any patient of ACS for risk stratification and early possible intervention.

**Conflict of Interest**

None.
References


